AGY THERAPEUTICS PRESENTS AT CHASE HAMBRECHT & QUIST 19TH ANNUAL HEALTHCARE CONFERENCE
SOUTH SAN FRANCISCO, Calif. January 8, 2001 AGY Therapeutics, Inc. announced it is presenting today at the 19th Annual Chase Hambrecht & Quist Healthcare Conference in San Francisco, California. Karoly Nikolich, Ph.D., AGY Therapeutics' president and chief executive officer, will deliver the presentation, which will provide an overview of the company's direction, research and development platform and partnering strategy.
"We are pleased to be among the select group of private companies invited to present at this conference," said Dr. Nikolich. "This is our first public appearance in the biotechnology community since our founding, and we hope it serves to establish our presence as an innovative company dedicated to treating central nervous system diseases."
Dr. Nikolich and Robert Swanson, former chief executive officer and chairman of the board, founded AGY Therapeutics in 1998. Since then, the company has successfully developed and utilized the imAGYne platform technology, a proprietary, high-throughput genomics and informatics platform which analyzes models of central nervous system disease and identifies targets and novel therapeutics that interfere with the intra- and extra- cellular signaling (mechanistic) pathways underlying these diseases.
AGY Therapeutics' research and development activities are being performed in stroke, epilepsy, Alzheimer's disease, Parkinson's disease, brain tumors, depression, schizophrenia and obesity, comprising multibillion-dollar markets for which there are strong, immediate, unmet medical needs.
ABOUT AGY THERAPEUTICS, INC.
AGY Therapeutics, Inc. is a privately held biopharmaceutical company focused on developing therapeutic products for the treatment of diseases of the central nervous system. With its proprietary imAGYne, imArrays and imFormatics platforms, AGY has built a unique knowledge base of the neuroprotective capacities and vulnerabilities of the nervous system.
This news release contains forward-looking statements about future research and development efforts. These statements represent our judgment as of the date of this news release and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. In particular, we face risks and uncertainties that further research into these genes may not go forward as planned or that future scientific data on these genes may not provide supportive data for the diseases we are targeting.